Neuroproteomics tools in clinical practice

Shevchenko, Ganna; Konzer, Anne; Musunuri, Sravani; Bergquist, Jonas

doi:10.1016/j.bbapap.2015.01.016

Cited by 36 publications

(31 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…proteomics. Proteomics was the first overall approach applied to health and proteomics techniques have largely evolved over many years [59]. Whatever the approach, many discrepancies may be listed among the different published studies, but in the end the same pathways have been highlighted.…”

Section: Transcriptsmentioning

confidence: 98%

“…Whatever the approach, many discrepancies may be listed among the different published studies, but in the end the same pathways have been highlighted. Metabolites linked to oxidative stress (4-HNE, 8-hydroxy-2'-deoxyguanosine cyclophilin A), inflammation (IL6, IL17, MCP1, Vitamin D binding protein, tau proteins, glycans, galectin 3), iron metabolism (ferritin), neuroprotection, (cystatin C), neuroaxonal degeneration (NFL, NFH, NFHSMI35, pNFH), BBB/BSCB permeability (MMP-9, MMPP-2), and motor neuron inclusion (TDP43) [59][60][61][62][63][64][65][66][67] have all been highlighted.…”

Section: Transcriptsmentioning

confidence: 99%

See 1 more Smart Citation

Further development of biomarkers in amyotrophic lateral sclerosis

Blasco

Vourc’h

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

In this review, we specifically focus on biology and imaging markers. We detail the innovative field of 'omics' approach and imaging and explain their limits to be useful in routine practice. We describe the most relevant biomarkers and suggest some perspectives for biomarker research. Expert commentary: The successive failures of clinical trials in ALS underline the need for new strategy based on innovative tools to stratify patients and to evaluate their responses to treatment. Biomarker data may be useful to improve the designs of clinical trials. Biomarkers are also needed to better investigate disease pathophysiology, to identify new therapeutic targets, and to improve the performance of clinical assessments for diagnosis and prognosis in the clinical setting. A consensus on the best management of neuroimaging and 'omics' methods is necessary and a systematic independent validation of findings may add robustness to future studies.

show abstract

Section: Transcriptsmentioning

confidence: 98%

Section: Transcriptsmentioning

confidence: 99%

Further development of biomarkers in amyotrophic lateral sclerosis

Blasco

Vourc’h

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…Defined as the quantitative or semi-quantitative analysis of the whole protein content of a biological fluid or cell, proteomics can explore a variety of fluids and tissues, usually with mass spectrometry 63 .…”

Section: The Importance Of Biomarkersmentioning

confidence: 99%

Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection

Blasco

Patin

Andres

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Age-related neurodegenerative disorders are fast becoming major public health problems for the world's aging populations. Several agents offer promise in the near-term, but drug development is hampered by an interrelated cycle of obstacles surrounding etiological, physiological, and biomarkers discovery. It is time for the type of government-funded, public-supported offensive on neurodegenerative disease that has been effective in other fields.

show abstract

“…The use of spectral counting and/or MS1 intensity methods in neuroproteomics is vast and usually alternates between the use of one type or another [9,159,160]. However, some reports combine the two methods to improve the results obtained, such as in the case of the interactomics study of the AMPA receptor performed in collaboration with our group [161] where both spectral counting and MS1 intensity were used to identify the truly positive interactors from the negative control.…”

Section: Ms1 Signaling Intensity or Area Under The Curve (Auc)mentioning

confidence: 99%

“…Further quantitative neuroproteomics studies were already summarized in several reviews [9,159,160].…”

Section: Ms1 Signaling Intensity or Area Under The Curve (Auc)mentioning

confidence: 99%

Neuroproteomics — LC-MS Quantitative Approaches

Santa¹,

Anjo²,

Mendes³

et al. 2015

Recent Advances in Proteomics Research

View full text Add to dashboard Cite

Neuroproteomics is a scientific field that aims to study all the proteins of the central nervous system, their expression, function, and interactions. The central nervous system is intricate and heterogeneous, and the study of its proteome is consequently complex, with many biological questions still requiring deep investigation. For this, mass spectrometry approaches, most often coupled with liquid chromatography (LC-MS), have been the number one choice in proteomics, and over the years it has added many important findings to the field. At this point it is important that proteomics turns to the quantitative expression of proteins instead of only identifying which proteins are present in a given sample, much because the most important alterations may be slight alterations in the quantity of a protein in a given situation. Therefore, many LC-MS quantitative approaches have been developed relying on the labeling of the proteins or even by using label-free techniques.In this chapter, a brief description of the principles and procedures of several approaches used for relative and absolute, targeted and untargeted quantification of proteins is presented, complemented with a literature revision of their application in the neurosciences field.

show abstract

Neuroproteomics tools in clinical practice

Cited by 36 publications

References 128 publications

Further development of biomarkers in amyotrophic lateral sclerosis

Further development of biomarkers in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection

Neuroproteomics — LC-MS Quantitative Approaches

Contact Info

Product

Resources

About